Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Preclinical assessment with clinical validation of Selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma.

Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D, Mahipal A, Dyson G, Kamgar M, Al Hallak MN, Tesfaye A, Kim S, Shidham V, Ramzi M, Philip PA.

Clin Cancer Res. 2019 Dec 12. pii: clincanres.1728.2019. doi: 10.1158/1078-0432.CCR-19-1728. [Epub ahead of print]

PMID:
31831564
2.

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.

Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS.

Cancers (Basel). 2019 Nov 29;11(12). pii: E1902. doi: 10.3390/cancers11121902.

3.

A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer.

Block CJ, Dyson G, Campeanu IJ, Watza D, Ratnam M, Wu G.

Sci Rep. 2019 Nov 28;9(1):17807. doi: 10.1038/s41598-019-54282-z.

4.

COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.

Watza D, Lusk CM, Dyson G, Purrington KS, Wenzlaff AS, Neslund-Dudas C, Soubani AO, Gadgeel SM, Schwartz AG.

Int J Cancer. 2019 Nov 10. doi: 10.1002/ijc.32780. [Epub ahead of print]

PMID:
31709530
5.

Maspin differential expression patterns as a potential marker for targeted screening of esophageal adenocarcinoma/gastroesophageal junction adenocarcinoma.

Dzinic SH, Mahdi Z, Bernardo MM, Vranic S, Beydoun H, Nahra N, Alijagic A, Harajli D, Pang A, Saliganan DM, Rahman AM, Skenderi F, Hasanbegovic B, Dyson G, Beydoun R, Sheng S.

PLoS One. 2019 Apr 19;14(4):e0215089. doi: 10.1371/journal.pone.0215089. eCollection 2019.

6.

Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Lusk CM, Watza D, Dyson G, Craig D, Ratliff V, Wenzlaff AS, Lonardo F, Bollig-Fischer A, Bepler G, Purrington K, Gadgeel S, Schwartz AG.

Clin Cancer Res. 2019 Jul 15;25(14):4300-4308. doi: 10.1158/1078-0432.CCR-18-2439. Epub 2019 Apr 12.

PMID:
30979741
7.

Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.

Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A.

Mol Oncol. 2019 Apr;13(4):894-908. doi: 10.1002/1878-0261.12444. Epub 2019 Mar 1.

8.

Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center.

Zhang KJ, Dyson G, Gatz JL, Silverman ME, Tesfaye AA, Shields AF, Philip PA.

Am J Clin Oncol. 2019 Mar;42(3):243-246. doi: 10.1097/COC.0000000000000507.

9.

The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Dyson G, Farran B, Bolton S, Craig DB, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun LK, Bock CH.

Am J Cancer Res. 2018 Oct 1;8(10):2088-2095. eCollection 2018.

10.

Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes.

Watza D, Lusk CM, Dyson G, Purrington KS, Chen K, Wenzlaff AS, Ratliff V, Neslund-Dudas C, Bepler G, Schwartz AG.

Carcinogenesis. 2018 Dec 31;39(12):1447-1454. doi: 10.1093/carcin/bgy119.

PMID:
30202894
11.

IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.

Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend WN, McCarthy CE, Reyes J, Wei WZ, Viola-Villegas NT.

Cancer Res. 2018 Oct 1;78(19):5706-5717. doi: 10.1158/0008-5472.CAN-18-0253. Epub 2018 Aug 16.

12.

Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.

Teslow EA, Bao B, Dyson G, Legendre C, Mitrea C, Sakr W, Carpten JD, Powell I, Bollig-Fischer A.

Mol Oncol. 2018 Jun;12(7):1138-1152. doi: 10.1002/1878-0261.12316. Epub 2018 May 24.

13.

A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Farran B, Dyson G, Craig D, Dombkowski A, Beebe-Dimmer JL, Powell IJ, Podgorski I, Heilbrun L, Bolton S, Bock CH.

Carcinogenesis. 2018 Apr 5;39(4):556-561. doi: 10.1093/carcin/bgy025.

14.

Integrating 5hmC and gene expression data to infer regulatory mechanisms.

Mitrea C, Wijesinghe P, Dyson G, Kruger A, Ruden DM, Draghici S, Bollig-Fischer A.

Bioinformatics. 2018 May 1;34(9):1441-1447. doi: 10.1093/bioinformatics/btx777.

15.

The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.

Bock CH, Jay AM, Dyson G, Beebe-Dimmer JL, Cote ML, Hou L, Howard BV, Desai P, Purrington K, Prentice R, Simon MS.

Breast Cancer Res Treat. 2018 Feb;167(3):741-749. doi: 10.1007/s10549-017-4521-0. Epub 2017 Oct 24.

16.

HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer.

Jung YS, Najy AJ, Huang W, Sethi S, Snyder M, Sakr W, Dyson G, Hüttemann M, Lee I, Ali-Fehmi R, Franceschi S, Struijk L, Kim HE, Kato I, Kim HC.

Oncotarget. 2017 May 16;8(31):51530-51541. doi: 10.18632/oncotarget.17887. eCollection 2017 Aug 1.

17.

Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.

Stafford JL, Dyson G, Levin NK, Chaudhry S, Rosati R, Kalpage H, Wernette C, Petrucelli N, Simon MS, Tainsky MA.

PLoS One. 2017 Jun 7;12(6):e0178450. doi: 10.1371/journal.pone.0178450. eCollection 2017.

18.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

19.

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A.

Sci Rep. 2017 Mar 10;7:44125. doi: 10.1038/srep44125.

20.

ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding.

Walker AR, Silvestrov P, Müller TA, Podolsky RH, Dyson G, Hausinger RP, Cisneros GA.

PLoS Comput Biol. 2017 Feb 23;13(2):e1005345. doi: 10.1371/journal.pcbi.1005345. eCollection 2017 Feb.

21.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DS, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Pang A, Harajli D, Sakr WA, Sheng S.

Cancer Res. 2017 Feb 15;77(4):886-896. doi: 10.1158/0008-5472.CAN-16-2219. Epub 2016 Dec 6.

22.

Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer.

Kato I, Dyson G, Snyder M, Kim HR, Severson RK.

J Radiat Oncol. 2016 Sep;5(3):279-286. Epub 2016 Jan 27.

23.

Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.

Zaki M, Dominello M, Dyson G, Gadgeel S, Wozniak A, Miller S, Paximadis P.

Clin Lung Cancer. 2017 Jan;18(1):e21-e26. doi: 10.1016/j.cllc.2016.07.005. Epub 2016 Jul 22.

24.

How do women with secondary breast cancer experience telling their adolescent children about their diagnosis?

Lalayiannis L, Asbury N, Dyson G, Walshe A.

J Health Psychol. 2018 Aug;23(9):1223-1233. doi: 10.1177/1359105316648484. Epub 2016 Jun 5.

PMID:
27270684
25.

Pretreatment computed tomographic gross tumor volume as predictor of persistence of tracheostomy and percutaneous endoscopic gastrostomy tube in patients undergoing larynx preservation.

Hurst NJ Jr, Pereira LM, Dominello MM, Dyson G, Laszewski P, Robinette N, Lin HS, Yoo G, Sukari A, Kim H.

Head Neck. 2016 Oct;38(10):1455-8. doi: 10.1002/hed.24458. Epub 2016 Apr 30.

26.

Role of cancer stem cells in racial disparity in colorectal cancer.

Farhana L, Antaki F, Anees MR, Nangia-Makker P, Judd S, Hadden T, Levi E, Murshed F, Yu Y, Van Buren E, Ahmed K, Dyson G, Majumdar AP.

Cancer Med. 2016 Jun;5(6):1268-78. doi: 10.1002/cam4.690. Epub 2016 Mar 14.

27.

12-HETER1/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression.

Honn KV, Guo Y, Cai Y, Lee MJ, Dyson G, Zhang W, Tucker SC.

FASEB J. 2016 Jun;30(6):2360-9. doi: 10.1096/fj.201500076. Epub 2016 Mar 10.

28.

Whole-exome sequencing reveals genetic variability among lung cancer cases subphenotyped for emphysema.

Lusk CM, Wenzlaff AS, Dyson G, Purrington KS, Watza D, Land S, Soubani AO, Gadgeel SM, Schwartz AG.

Carcinogenesis. 2016 Feb;37(2):139-144. doi: 10.1093/carcin/bgv248. Epub 2015 Dec 30.

29.

Ten-year trends in safe radiation therapy delivery and results of a radiation therapy quality assurance intervention.

Dominello MM, Paximadis P, Zaki M, Hammoud A, Campbell S, Komajda M, Dyson G, Bossenberger T, Burmeister J.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e665-71. doi: 10.1016/j.prro.2015.08.004. Epub 2015 Aug 28.

PMID:
26547830
30.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

31.

A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.

Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, Saed GM.

PLoS One. 2015 Aug 24;10(8):e0135739. doi: 10.1371/journal.pone.0135739. eCollection 2015.

32.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
33.

Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.

Najy AJ, Dyson G, Jena BP, Lin CY, Kim HR.

Am J Physiol Cell Physiol. 2016 Feb 15;310(4):C293-304. doi: 10.1152/ajpcell.00043.2015. Epub 2015 Jul 8.

34.

Cytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.

Bollig-Fischer A, Michelhaugh SK, Wijesinghe P, Dyson G, Kruger A, Palanisamy N, Choi L, Alosh B, Ali-Fehmi R, Mittal S.

Oncotarget. 2015 Jun 10;6(16):14614-24.

35.

Hydrazinobenzoylcurcumin inhibits androgen receptor activity and growth of castration-resistant prostate cancer in mice.

Wu M, Kim SH, Datta I, Levin A, Dyson G, Li J, Kaypee S, Swamy MM, Gupta N, Kwon HJ, Menon M, Kundu TK, Reddy GP.

Oncotarget. 2015 Mar 20;6(8):6136-50.

36.

Intratumoral lymphatic vessel density as a predictor of progression-free and overall survival in locally advanced laryngeal/hypopharyngeal cancer.

Hurst NJ Jr, Dominello M, Dyson G, Jaratli H, Sharma M, Ahmed YK, Melkane AE, Rose C, Jacobs J, Giorgadze T, Kim H.

Head Neck. 2016 Apr;38 Suppl 1:E417-20. doi: 10.1002/hed.24011. Epub 2015 Jun 29.

PMID:
25641342
37.

Considering race and the potential for ERG expression as a biomarker for prostate cancer.

Powell IJ, Dyson G, Chinni SR, Bollig-Fischer A.

Per Med. 2014;11(4):409-412.

38.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. doi: 10.1016/j.bbmt.2014.10.004. Epub 2014 Oct 16.

39.

Maspin expression in prostate tumor elicits host anti-tumor immunity.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S.

Oncotarget. 2014 Nov 30;5(22):11225-36.

40.

Subgroups at high risk for ischaemic heart disease:identification and validation in 67 000 individuals from the general population.

Frikke-Schmidt R, Tybjærg-Hansen A, Dyson G, Haase CL, Benn M, Nordestgaard BG, Sing CF.

Int J Epidemiol. 2015 Feb;44(1):117-28. doi: 10.1093/ije/dyu215. Epub 2014 Oct 30.

41.

Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer.

Vasudevan A, Yu Y, Banerjee S, Woods J, Farhana L, Rajendra SG, Patel A, Dyson G, Levi E, Maddipati KR, Majumdar AP, Nangia-Makker P.

Cancer Prev Res (Phila). 2014 Nov;7(11):1138-48. doi: 10.1158/1940-6207.CAPR-14-0177. Epub 2014 Sep 5.

42.

Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study.

Lusk CM, Dyson G, Clark AG, Ballantyne CM, Frikke-Schmidt R, Tybjærg-Hansen A, Boerwinkle E, Sing CF.

Hum Genet. 2014 Sep;133(9):1105-16. doi: 10.1007/s00439-014-1451-3. Epub 2014 Jun 3.

43.

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.

Hillman GG, Lonardo F, Hoogstra DJ, Rakowski J, Yunker CK, Joiner MC, Dyson G, Gadgeel S, Singh-Gupta V.

Transl Oncol. 2014 May 23. pii: S1936-5233(14)00037-0. doi: 10.1016/j.tranon.2014.04.002. [Epub ahead of print]

44.

Efficient identification of context dependent subgroups of risk from genome-wide association studies.

Dyson G, Sing CF.

Stat Appl Genet Mol Biol. 2014 Apr 1;13(2):217-26. doi: 10.1515/sagmb-2013-0062.

45.

Evaluation of the effect of genetic variation on the relationship between statins, cardiovascular disease and cancer.

Desai P, Jay A, Bock C, Dyson G, Okwuosa T, Simon MS.

Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):183-92. Review.

46.

Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization.

Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA.

ISRN Oncol. 2013 Sep 15;2013:538376. doi: 10.1155/2013/538376. eCollection 2013.

47.

Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25.

Azmi AS, Bollig-Fischer A, Bao B, Park BJ, Lee SH, Yong-Song G, Dyson G, Reddy CK, Sarkar FH, Mohammad RM.

BMC Syst Biol. 2013 Sep 3;7:85. doi: 10.1186/1752-0509-7-85.

48.

Hypothesis driven single nucleotide polymorphism search (HyDn-SNP-S).

Swett RJ, Elias A, Miller JA, Dyson GE, Andrés Cisneros G.

DNA Repair (Amst). 2013 Sep;12(9):733-40. doi: 10.1016/j.dnarep.2013.06.001. Epub 2013 Jul 5. Erratum in: DNA Repair (Amst). 2014 Mar;15:60.

49.

Copper and silver complexes bearing flexible hybrid scorpionate ligand mpBm.

Owen GR, Gould PH, Moore A, Dyson G, Haddow MF, Hamilton A.

Dalton Trans. 2013 Aug 21;42(31):11074-81. doi: 10.1039/c3dt51286j.

PMID:
23799531
50.

Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.

Sethi S, Kong D, Land S, Dyson G, Sakr WA, Sarkar FH.

Am J Transl Res. 2013;5(2):200-11. Epub 2013 Mar 28.

Supplemental Content

Support Center